Stock Code: 000028/200028 Notice No.: 2022-23
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.The First Quarterly Report for 2022
The Company and whole members of the BOD guarantee that the information disclosed is true
accurate and complete and there are no any fictitious records misleading statements or important
omissions.Important content reminder:
1. Board of Directors Supervisory Committee all directors supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements misleading statements or important omissions carried in this report and shall take all
responsibilities individual and/or joint for the reality accuracy and completion of the whole contents.
2. Principal of the Company Person in Charge of Accounting Works and Person in Charge of Accounting Organ
(Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic accurate
and complete.
3. Whether the First Quarterly Report has been audited or not
□Yes √No
I. Main financial data
(i) Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□Yes√ No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 17150856946.54 16049966325.75 6.86%
Net profit attributable to shareholders of
252361872.69328800560.24-23.25%
the listed company (RMB)
Net profit attributable to shareholders of
the listed company after deducting 242244636.06 321593612.98 -24.67%
non-recurring gains and losses (RMB)
Net cash flow arising from operating
-217452223.38-306748999.2429.11%
activities (RMB)
Basic earnings per share (RMB/Share) 0.59 0.77 -23.38%
Diluted earnings per share (RMB/Share) 0.59 0.77 -23.38%
Weighted average ROE 1.68% 2.33% 0.65 percentage points
1down
Changes of this period-end
End of this period End of last period over same period-end of last
year
Total assets (RMB) 44844103338.63 42783682431.81 4.82%
Owners’ equity attributable to shareholders
15177183542.8114924938052.501.69%
of listed company (RMB)
Explanation on the business performance and financial status:
The Company achieved operation income of 17151 million yuan for the first quarter of 2022 a year-on-year increase of 6.86%;
operation profit was 375 million yuan 20.42% down from a year earlier; the net profit attributable to shareholder of listed company
was 252 million yuan decrease of 23.25% on a year-on-year basis the basic EPS decreased by 23.38% correspondingly and
weighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19 the performance from
affiliates declined and the investment earnings decreased accordingly. Meanwhile the customer flow from retail segment drops due
to the epidemic and the new stores operated in 2021 have a large initial investment the benefits are not yet visible with shrinking
profit space.The distribution segment has an operation income of 12171 million yuan a year-on-year growth of 7.45%; net profit was 210
million yuan a year-on-year increase of 10.40%. the retail segment has 5238 million yuan from the operation income a year-on-year
increase of 5.11% and achieved a net profit of 32 million yuan down 63.80% on a year-on-year basis.(ii) Items of non-recurring gains and losses
√ Applicable □ Not applicable
Unit: RMB/CNY
Item Current amount Note
The gains on disposal of
Gains/losses from the disposal of non-current asset (including the
785738.83 right-to-use asses arising from
write-off that accrued for impairment of assets)
off-lease in the period
Governmental subsidy calculated into current gains and
losses(while closely related with the normal business of the Mainly the various special
Company the government subsidy that accord with the provision 15562891.34 subsidies and tax rebates received
of national policies and are continuously enjoyed in line with a in the Period
certain standard quota or quantity are excluded)
Reversal of the account receivable depreciation reserves subject
1632768.34
to separate impairment test
Other non-operating income and expenses other than the above 1205854.08
Other gains/losses items that meet the definition of non-recurring
1789818.44
gains/losses
Less: impact on income tax 5104445.81
Impact on minority shareholders’ equity (post-tax) 5755388.59
Total 10117236.63 --
Details of other gains/losses items that meet the definition of non-recurring gains/losses:
□ Applicable √ Not applicable
2There are no other gains/losses items that meet the definition of non-recurring gains/losses in the Company.
Explain the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A
Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss
□ Applicable √ Not applicable
There are no items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A
Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss
(iii) Particulars about material changes in items of main accounting statement and financial index and explanations of
reasons
√ Applicable □Not applicable
(1)Receivable financing: decrease of 557.8708 million yuan from beginning of the Period with a growth rate of -54.31% mainly due
to the increase in discounting of bank acceptance in the Period;
(2) Construction in progress: decrease of 15.0976 million yuan from beginning of the Period with a growth rate of -30.29% mainly
because the ERP project transfer-out after completion & acceptance;
(3) Short-term borrowings: increase of 1108.1141 million yuan from beginning of the Period with a growth rate of 57.40% mainly
due to the increase in financing with the invoice of account payable;
(4) Employee benefits payable: decrease of 114.3872 million yuan from beginning of the Period with a growth rate of -33.62%
mainly because the wages and bonuses accrued in the prior year are paid in the Period;
(5) Other incomes: a year-on-year increase of 11.3852 million yuan with a growth rate of 83.37% mainly because various subsidies
received in the Period and the tax relief increased on a year-on-year basis;
(6) Investment income: a year-on-year decrease of 67.8440 million yuan with a growth rate of -74.30% mainly because the
performance from affiliates declined and the investment earnings decreased accordingly;
(7) Credit impairment losses: a year-on-year increase of 8.7011 million yuan with a growth rate of 50.60% mainly due to the
increase of account receivable at period-end compared to the same period of last year for the sales up; affected by the epidemic
medical insurance allocation was delayed the capital operation from hospital are relatively tight which had a certain impact on the
receivable collection of the Company turnover days of the receivable increase to some extent than the bad debt provision goes up
correspondingly;
(8) Impairment losses: a year-on-year decrease of 1.8342 million yuan with a growth rate of -52.58% mainly due to the decrease in
provision for inventory falling price reserves on a year-on-year basis;
(9) Gain on disposal of assets: a year-on-year increase of 0.7065 million yuan with a growth rate of 259.86% mainly due to the
increase in earnings on a year-on-year basis resulting from disposal of the right-of-use assets for vacating from retail stores.
(10)Non-operating income: a year-on-year decrease of 4.0821 million yuan with a growth rate of -64.08% mainly because in the
Period the payable without payment requirements written off declined from a year earlier;
(11) Non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20% mainly because the
net profit attributable to owners of parent company from subsidiary-Sinopharm Holding Guoda Drugstore Co. Ltd.(hereinafter
referred to as Guoda Drugstore) declined on a year-on-year basis accordingly the gains/losses of minority attributable to the
strategic investor of the Group-Walgreens Boots Alliance(Hong Kong)Investments Limited (hereinafter referred to as WBA)
decreased on a year-on-year basis;
(12) Total comprehensive income attributable to non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a
growth rate of -30.20% mainly because the net profit attributable to owners of parent company from subsidiary-Guoda Drugstore
declined on a year-on-year basis accordingly the gains/losses of minority attributable to the strategic investor of the Group- WBA
decreased on a year-on-year basis;
(13) Receipts of taxes and surcharges refunds: a year-on-year decrease of 4.7192 million yuan with a growth rate of -84.00% mainly
3due to the year-on-year decline in enterprise income tax refunds received in the Period;
(14) Other cash receipts relating to operating activities: a year-on-year decrease of 64.1937 million yuan with a growth rate of
-30.61% mainly because the reserve funds for epidemic-specific deposits and security deposit received in the Period declined from a
year earlier;
(15) Cash receipts from returns of investments: a year-on-year decrease of 2.9974 million yuan with a growth rate of -100.00%
mainly because in same period of last year received the withdrawal payment from part of the projects of Sinopharm Zhongjin
Medical Industry Fund and there was no such matter occurred in the Period;
(16) Cash received from investment income: a year-on-year decrease of 3.5996 million yuan with a growth rate of -100.00% mainly
because in same period of last year received dividend payment from projects of Sinopharm Zhongjin Medical Industry Fund and
there was no such matter occurred in the Period;
(17) Net cash receipts from disposal of fixed assets intangible assets and other long-term assets: a year-on-year decrease of 0.2423
million yuan with a growth rate of -74.08% mainly because the cash received in the Period from fixed assets disposal decreased
from a year earlier;
(18) Total cash inflows from investing activities: a year-on-year decrease of 6.8393 million yuan with a growth rate of -98.78%
mainly because in same period of last year received dividend payment and withdrawal payment from projects of Sinopharm
Zhongjin Medical Industry Fund and there were no such matters occurred in the Period;
(19) Cash payments for investments: a year-on-year decrease of 8.7574 million yuan with a growth rate of -32.34% mainly because
the payment for rental transfer fees in the Period declined from a year earlier paid by subsidiary - Guoda Drugstore;
(20) Net cash payments for acquisition of subsidiaries and other business units: a year-on-year decrease of 73.1595 million yuan with
a growth rate of -100.00% mainly because in same period of last year subsidiary Guoda Drugstore paid for the acquisition of a
subsidiary and there was no such matter occurred in the Period;
(21) Total cash outflows from investing activities: a year-on-year decrease of 67.8542 million yuan with a growth rate of -41.83%
mainly because in same period of last year subsidiary Guoda Drugstore paid for the acquisition of a subsidiary and there was no
such matter occurred in the Period;
(22) Net cash flows from investing activities: a year-on-year increase of 61.0148 million yuan with a growth rate of 39.29% mainly
because in same period of last year subsidiary Guoda Drugstore paid for the acquisition of a subsidiary and there was no such matter
occurred in the Period;
(23) Cash proceeds from investments by others: a year-on-year decrease of 4.98 million yuan with a growth rate of -84.69% mainly
due to the year-on-year decrease in investment received from minority during the Period;
(24) Other cash receipts relating to financing activities: a year-on-year decrease of 192.0255 million yuan with a growth rate of
-64.56% mainly because in the Period the recovery of factoring business and repayment difference declined on a year-on-year basis;
(25) Cash repayments for debts: a year-on-year increase of 94.2452 million yuan with a growth rate of 53.17% mainly due to the
increase in repayment of loans due in the Period;
(26) Total cash outflows from financing activities: a year-on-year increase of 161.1150 million yuan with a growth rate of 33.41%
mainly because repayment of loans from financial institutions and the rents paid for increasing retail stores in the Period increased on
a year-on-year basis;
(27) Net cash flows from financing activities: a year-on-year decrease of 276.5162 million yuan with a growth rate of -71.17%
mainly because in the Period the recovery of factoring business and repayment difference declined on a year-on-year basis the rents
paid for increasing retail stores in the Period increased on a year-on-year basis;
(28) Effect of foreign exchange rate changes on cash and cash equivalents: a year-on-year increase of 1989.89 yuan with a growth
rate of 81.53% mainly due to the change of exchange rates;
(29) Net increase of cash and cash equivalents :a year-on-year decrease of 126.2026 million yuan with a growth rate of -171.70%
mainly because in the Period the recovery of factoring business and repayment difference declined on a year-on-year basis the rents
paid for increasing retail stores in the Period increased on a year-on-year basis.
4II. Shareholders
(i) Total number of common shareholders and preference shareholders with voting rights recovered and
top ten shareholders
Unit: Share
Total preference shareholders
Total number of common
with voting rights recovered at
shareholders at the end of report 44112 0
end of reporting period (if
period
applicable)
Top ten shareholders
Amount of Information of shares pledged
Shareholder’s Nature of Proportion of Amount of shares
lock-up shares tagged or frozen
name shareholder shares held held
held State of share Amount
Sinopharm Group State-owned
56.06%2399999915505770
Co. Ltd. Corporation
FIRST SENTIER
INVESTORS
GLOBAL
UMBRELLA Foreign
2.52%10802495
FUND PLC - Corporation
FSSA CHINA
GROWTH
FUND
Hong Kong
Securities Foreign
2.28%9751340
Clearing Corporation
Company Ltd.China National
Pharmaceutical State-owned
1.24%5323043
Foreign Trade Corporation
Corp.National Social Domestic non
Security Fund state-owned 1.07% 4590032
413 Portfolio Corporation
BBH BOS S/A
FIDELITY FD - Foreign
0.78%3358761
CHINA FOCUS Corporation
FD
Fidelity
Foreign
Investment 0.54% 2301737
Corporation
Management
5(Hong Kong)
Limited - Client’s
fund
ICBC-Guolian
Andesheng Domestic non
Small Selected state-owned 0.38% 1632000
Securities Corporation
Investment Fund
CPIC Fund
-China Pacific
Life Insurance
Co. Ltd. -
with-profit
insurance- CPIC
Domestic non
Fund China
state-owned 0.34% 1470224
Pacific Life
Corporation
Equity Relative
Income
(Guaranteed
Dividend) single
assets
management plan
VANGUARD
EMERGING
Foreign
MARKETS 0.34% 1456150
Corporation
STOCK INDEX
FUND
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Group Co. Ltd. 234494221 234494221
shares
FIRST SENTIER INVESTORS Domestically
GLOBAL UMBRELLA FUND PLC 10802495 listed foreign 10802495
- FSSA CHINA GROWTH FUND shares
Hong Kong Securities Clearing RMB ordinary
97513409751340
Company Ltd. shares
China National Pharmaceutical RMB ordinary
53230435323043
Foreign Trade Corp. shares
National Social Security Fund 413 RMB ordinary
45900324590032
Portfolio shares
6Domestically
BBH BOS S/A FIDELITY FD -
3358761 listed foreign 3358761
CHINA FOCUS FD
shares
Fidelity Investment Management RMB ordinary
23017372301737
(Hong Kong) Limited - Client’s fund shares
ICBC-Guolian Andesheng Small RMB ordinary
16320001632000
Selected Securities Investment Fund shares
CPIC Fund -China Pacific Life
Insurance Co. Ltd. - with-profit
insurance- CPIC Fund China Pacific RMB ordinary
14702241470224
Life Equity Relative Income shares
(Guaranteed Dividend) single assets
management plan
Domestically
VANGUARD EMERGING
1456150 listed foreign 1456150
MARKETS STOCK INDEX FUND
shares
Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation
Explanation on associated have the same actual controller which is China National Pharmaceutical Group Corporation.relationship among the aforesaid It is unknown that there exists no associated relationship or belongs to the consistent actionist
shareholders among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.(ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferred
stock held
□ Applicable √ Not applicable
III. Other important matters
□ Applicable √ Not applicable
IV. Quarterly financial statements
(i) Financial statement
1. Consolidate Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.March 31 2022
Unit: RMB/CNY
Item Ending balance Opening balance
Current assets:
Cash and bank balances 4867544893.18 5126159080.94
Settlement provisions
Capital lent
Trading financial assets
7Derivative financial assets
Notes receivable 642430566.93 680196380.57
Accounts receivable 18445260411.58 15964603345.91
Receivable financing 469356116.33 1027226940.21
Advances to suppliers 477599161.72 520930545.31
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance receivable
Other receivables 654794241.77 718089129.10
Including: Interest receivable
Dividend receivable
Buying back the sale of financial assets
Inventories 8058564605.96 7621541595.08
Contract assets 29728855.46 29061159.52
Assets held for sale
Non-current asset due within one year
Other current assets 140830256.92 160607355.66
Total current assets 33786109109.85 31848415532.30
Non-current assets:
Loans and payments on behalf
Debt investment
Other debt investment
Long-term account receivable
Long-term equity investments 2501295548.16 2459832546.74
Other equity instruments investment 62488312.99 62488312.99
Other non-current financial assets 135974908.51 135974908.51
Investment properties 112808525.33 113981497.23
Fixed assets 850200561.56 868626258.43
Construction in progress 34751943.39 49849506.70
Productive biological asset
Oil and gas asset
Right-of-use assets 2664487497.37 2575240340.00
Intangible assets 678354661.52 669926562.82
Expense on Research and Development
Goodwill 2775645585.32 2775645585.32
Long-term prepaid expenses 621061288.02 633975441.76
Deferred tax assets 154699087.40 129740169.77
Other non-current assets 466226309.21 459985769.24
Total non-current assets t 11057994228.78 10935266899.51
Total assets 44844103338.63 42783682431.81
Current liabilities:
Short-term borrowings 3038581281.11 1930467146.38
Loan from central bank
Capital borrowed
Trading financial liability
Derivative financial liability
8Notes payable 6759000854.12 7660216823.68
Accounts payable 10610876048.40 9057718968.14
Receipts in advance 18591112.89 19289567.44
Contract liabilities 429473280.23 431303231.37
Selling financial asset of repurchase
Absorbing deposit and interbank deposit
Security trading of agency
Security sales of agency
Employee benefits payable 225809878.05 340197125.33
Tax payable 307116334.60 337164080.19
Other payables 1907708455.77 1714746986.46
Including: Interest payable 37765231.34 31587062.03
Dividend payable 30140616.33 30140616.33
Commission charge and commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within one year 851459913.02 848328648.14
Other current liabilities 37309563.28 39585469.65
Total current liabilities 24185926721.47 22379018046.78
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 70137173.89 71637173.89
Bonds payable
Including: Preferred stock
Perpetual capital securities
Lease liabilities 1420668973.13 1375427877.28
Long-term payables 6938189.00 6938189.00
Long-term employee benefits payable 1202000.00 1202000.00
Provisions
Deferred income 85016983.16 86917051.78
Deferred tax liabilities 172433335.41 175948328.93
Other non-current liabilities 584974923.18 664381065.65
Total non-current liabilities 2341371577.77 2382451686.53
Total liabilities 26527298299.24 24761469733.31
Equity
Share capital 428126983.00 428126983.00
Other equity instrument
Including: Preferred stock
Perpetual capital securities
Capital surplus 4371621053.65 4371802107.43
Less: Inventory shares
Other comprehensive income 21938869.76 21874198.36
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 10141433144.90 9889071272.21
9Total equity attributable to owners of the parent 15177183542.81 14924938052.50
Non-controlling interests 3139621496.58 3097274646.00
Total equity 18316805039.39 18022212698.50
Total liabilities and equity 44844103338.63 42783682431.81
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
2. Consolidated Profit Statement
Unit: RMB/CNY
Item Current period Last period
I. Total operating income 17150856946.54 16049966325.75
Including: Operating revenue 17150856946.54 16049966325.75
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 16797706856.47 15663170079.60
Including: Operating costs 15227900206.53 14260591404.46
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of compensation
Net amount of withdrawal of insurance contract
reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 41939571.15 33744327.20
Selling expenses 1203497011.57 1080543941.75
Administrative expenses 264532679.98 237615927.36
R&D expense
Finance costs 59837387.24 50674478.83
Including: Interest expenses 72514879.45 68683688.49
Interest income 16770723.32 18058735.03
Add: other incomes 25040832.98 13655624.72
Investment income (Loss is listed with
23461476.6891305476.74
“-”)
Including: Investment income from
41579383.8092441826.44
associates
Income from the derecognition
of financial assets measured at amortised cost -18117907.12 -4735905.31
(Loss is listed with “-”)
Exchange income (Loss is listed with
“-”)
10Net exposure hedging income (Loss is
listed with “-”)
Income from change of fair value (Loss
is listed with “-”)
Credit impairment losses/ (Loss is listed
-25898207.09-17197080.80
with “-”)
Impairment losses (Loss is listed with
-1654289.70-3488500.85
“-”)
Gain on disposal of assets (Loss is listed
978407.63271889.26
with “-”)
III. Operating profits (Loss is listed with “-”) 375078310.57 471343655.22
Add: Non-operating income 2288693.57 6370834.89
Less: Non-operatingexpenses 600906.15 570737.09
IV. Total profit (Loss is listed with “-”) 376766097.99 477143753.02
Less: Income tax expenses 81994493.36 87580022.00
V. Net profit (Net loss is listed with “-”) 294771604.63 389563731.02
(i) Classify by business continuity
1. Profit or loss from continuing operations
294771604.63389563731.02(net loss listed with ‘-”)
2.termination of net profit (net loss listedwith ‘-”)
(ii) Classify by ownership
1. Owners of the parent 252361872.69 328800560.24
2. Non-controlling interests 42409731.94 60763170.78
VI. Other comprehensive income net of tax 64671.40 84503.76
Other comprehensive income net of tax
64671.4084503.76
attributable to owners of the parent
(i) Other comprehensive income items which
will not be reclassified subsequently to profit of
loss
1.Changes of the defined benefit
plans that re-measured
2.Other comprehensive income under
equity method that cannot be transfer to gain/loss
3.Change of fair value of investment
in other equity instrument
4.Fair value change of enterprise's
credit risk
5. Other
(ii) Other comprehensive income that will
64671.4084503.76
be reclassified to profit or loss
1. Other comprehensive income
using the equity method that may be reclassified 64671.40 84503.76
to profit or loss
2.Change of fair value of other debt
investment
3.Amount of financial assets
re-classify to other comprehensive income
4.Credit impairment provision for
other debt investment
5.Cash flow hedging reserve
6.Translation differences arising on
11translation of foreign currency financial
statements
7.Other
Net after-tax of other comprehensive income
attributable to minority shareholders
VII. Total comprehensive income 294836276.03 389648234.78
Total comprehensive income attributable to
252426544.09328885064.00
owners of the parent
Total comprehensive income attributable to
42409731.9460763170.78
non-controlling interests
VIII. Earnings per share:
(i) Basic earnings per share 0.59 0.77
(ii) Diluted earnings per share 0.59 0.77
Enterprise combine under the same control in the Period the combined party realized net profit of 0.00 Yuan before combination and
realized 0.00 Yuan at last period for combined party.Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
3. Consolidated Cash Flow Statement
Unit: RMB/CNY
Item Current period Last period
I. Cash flows from operating activities:
Cash received from sales of good or rendering of
16757405030.6215194724502.12
services
Net increase of customer deposit and interbank
deposit
Net increase of loan from central bank
Net increase of capital borrowed from other financial
institution
Cash received from original insurance contract fee
Net cash received from reinsurance business
Net increase of insured savings and investment
Cash received from interest commission charge and
commission
Net increase of capital borrowed
Net increase of returned business capital
Net cash received by agents in sale and purchase of
securities
Receipts of taxes and surcharges refunds 898760.75 5617976.11
Other cash receipts relating to operating activities 145551765.30 209745502.46
Total cash inflows from operating activities 16903855556.67 15410087980.69
Cash payments for goods and services 15413374469.33 14094028880.65
Net increase of customer loans and advances
Net increase of deposits in central bank and
interbank
12Cash paid for original insurance contract
compensation
Net increase of capital lent
Cash paid for interest commission charge and
commission
Cash paid for bonus of guarantee slip
Cash payments to and on behalf of employees 999525639.18 894497321.19
Payments of all types of taxes and surcharges 416425915.99 354054737.85
Other cash payments relating to operating activities 291981755.55 374256040.24
Total cash outflows from operating activities 17121307780.05 15716836979.93
Net cash flows from operating activities -217452223.38 -306748999.24
II. Cash flows from investing activities:
Cash receipts from returns of investments 2997441.73
Cash received from investment income 3599555.61
Net cash receipts from disposal of fixed assets
84789.95327119.50
intangible assets and other long-term assets
Net cash received from disposal of subsidiaries and
other units
Other cash receipts relating to investing activities
Total cash inflows from investing activities 84789.95 6924116.84
Cash payments to acquire fixed assets intangible assets
76023361.8761960648.98
and other long-term assets
Cash payments for investments 18322350.00 27079733.00
Net increase of mortgaged loans
Net cash payments for acquisition of subsidiaries and
73159498.29
other business units
Cash payments related to other investing activities
Total cash outflows from investing activities 94345711.87 162199880.27
Net cash flows from investing activities -94260921.92 -155275763.43
III. Cash flows from financing activities
Cash proceeds from investments by others 900000.00 5880000.00
Incl: Cash receipts from capital contributions from
900000.005880000.00
non-controlling interests of subsidiaries
Cash receipts from borrowings 649000000.00 567395696.23
Other cash receipts relating to financing activities 105391223.35 297416755.19
Total cash inflows from financing activities 755291223.35 870692451.42
Cash repayments for debts 271500000.00 177254802.73
Cash payments for distribution of dividends or profit
63873455.6159139307.66
and interest expenses
Incl: Dividends or profit paid to non-controlling
962881.36555825.80
shareholders of subsidiaries
Other cash payments relating to financing activities 307909948.17 245774326.14
Total cash outflows from financing activities 643283403.78 482168436.53
Net cash flows from financing activities 112007819.57 388524014.89
IV. Effect of foreign exchange rate changes on cash and
-450.89-2440.78
cash equivalents
V. Net increase of cash and cash equivalents -199705776.62 -73503188.56
Add: Cash and cash equivalents at beginning of the
4733512172.375405113257.99
year
VI. Cash and cash equivalents at end of year 4533806395.75 5331610069.43
13(ii) Audit report
Whether the 1st quarterly report has been audited or not
□Yes √ No
The 1st quarterly report of the Company has not been audited.China National Accord Medicines Corporation Ltd.Legal representative: Lin Zhaoxiong
April 28 2022
14
沪公网安备31011802005267号
